A Retrospective Cohort of Tumor-Induced Osteomalacia and Case Series of Malignant Disease
The Journal of Clinical Endocrinology & Metabolism · 2025
DOI: 10.1210/clinem/dgae183 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2025. Verfasst von Caroline Wei Shan Hoong und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology and Metabolism, Department of Medicine, Mayo Clinic Rochester, Rochester, MN 55905, USA. Hauptthemen laut MEDLINE: Paraneoplastic Syndromes, Neoplasms, Connective Tissue, Neoplasms. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 32 Literaturangaben.
Abstract (Originalsprache)
Context
Tumor-induced osteomalacia (TIO) is a rare condition with evidence mostly derived from case reports and case series.
Objective
We aimed to describe the clinical characteristics of a large cohort of patients diagnosed with TIO, with a focus on patients with nonlocalizing and malignant TIO.
Methods
This is a retrospective cohort of patients with TIO in an academic medical center, diagnosed between January 1998 and May 2023. We describe their demographics, biochemistries, tumor features, localization, treatment, and complications.
Results
Of 68 patients diagnosed with TIO, 49 (72%) were localizing and 5 (7.4%) were malignant. Of 50 patients who attempted localizing procedures, 29 (58%) achieved cure. Twenty (40%) had persistent disease due to the wrong tumor targeted, or refractory or recurrent tumors, despite up to 6 procedural attempts. There was no difference in demographics, phosphorus, or baseline fibroblast growth factor-23 (FGF23) levels between localizing vs nonlocalizing groups, and malignant vs nonmalignant groups. The lower extremity was the commonest site of localization (37%), with 47% in bone and 53% in soft tissue. Sixty percent of malignant cases were located in the trunk. Tumor size correlated with peak FGF23 (R = 0.566, P < .001) but was not associated with malignancy risk (P = .479). A cut-off FGF23 of >20 times upper limit of normal in the presence of normal renal function (P = .025) and recurrence after initial cure (P = .013) were factors significantly associated with malignancy. The nonlocalizing group had lower survival than the localizing group (P = .0097).
Conclusion
TIO is a condition with significant morbidity. Very high FGF23 levels and disease recurrence are associated with malignant disease. Reasons behind the observation of higher mortality in nonlocalizing TIO should be further explored.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Endocrinology and Metabolism, Department of Medicine, Mayo Clinic Rochester, Rochester, MN 55905, USA.
- Division of Endocrinology, Woodlands Health, National Healthcare Group, Singapore.
- Robert and Arlene Kogod Center on Aging, Mayo Clinic Rochester, Rochester, MN 55905, USA.
- Department of Laboratory Medicine and Pathology, Mayo Clinic Rochester, Rochester, MN 55905, USA.
ORCID-Profile: Caroline Wei Shan Hoong, Jad Sfeir, Alicia Algeciras-Schimnich, Bart Lyman Clarke
Zitieren
APA
Hoong, C. W. S., Sfeir, J., Algeciras-Schimnich, A., & Clarke, B. L. (2025). A Retrospective Cohort of Tumor-Induced Osteomalacia and Case Series of Malignant Disease. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgae183
Vancouver
Hoong CWS, Sfeir J, Algeciras-Schimnich A, Clarke BL. A Retrospective Cohort of Tumor-Induced Osteomalacia and Case Series of Malignant Disease. The Journal of Clinical Endocrinology & Metabolism. 2025. doi:10.1210/clinem/dgae183
BibTeX
@article{Hoong2025,
author = {Hoong, Caroline Wei Shan and Sfeir, Jad and Algeciras-Schimnich, Alicia and Clarke, Bart Lyman},
title = {A Retrospective Cohort of Tumor-Induced Osteomalacia and Case Series of Malignant Disease},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2025},
doi = {10.1210/clinem/dgae183}
}
EUVIMED